A Sequence-randomized, Open-label, 3-way Crossover, Single Oral Dose Clinical Trial to Investigate the Pharmacokinetic Characteristics and Safety/Tolerability According to Formulations of CKD-386 in Healthy Male Volunteers
Latest Information Update: 05 Apr 2021
At a glance
- Drugs CKD 386 (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 24 Apr 2019 New trial record